{"title":"乳腺癌、结直肠癌和非小细胞肺癌的生物标志物更新。","authors":"Jeffrey S Ross","doi":"10.1358/dnp.2010.23.1.1437316","DOIUrl":null,"url":null,"abstract":"<p><p>The integration of diagnostics into the selection, administration, dosing and monitoring of the use of anticancer drugs has continued to impact the pharmaceutical industry with particular emphasis on cancers of the breast, colon and lung. An update is given on the biomarkers for these cancers.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"23 1","pages":"82-8"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":"{\"title\":\"Biomarker update for breast, colorectal and non-small cell lung cancer.\",\"authors\":\"Jeffrey S Ross\",\"doi\":\"10.1358/dnp.2010.23.1.1437316\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The integration of diagnostics into the selection, administration, dosing and monitoring of the use of anticancer drugs has continued to impact the pharmaceutical industry with particular emphasis on cancers of the breast, colon and lung. An update is given on the biomarkers for these cancers.</p>\",\"PeriodicalId\":11325,\"journal\":{\"name\":\"Drug news & perspectives\",\"volume\":\"23 1\",\"pages\":\"82-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug news & perspectives\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1358/dnp.2010.23.1.1437316\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug news & perspectives","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dnp.2010.23.1.1437316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Biomarker update for breast, colorectal and non-small cell lung cancer.
The integration of diagnostics into the selection, administration, dosing and monitoring of the use of anticancer drugs has continued to impact the pharmaceutical industry with particular emphasis on cancers of the breast, colon and lung. An update is given on the biomarkers for these cancers.